Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.80 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinazoline SCHEMBL22833783 | 0.89 | EGFR (1.00) | EGFRPIK3CAPIK3CDKDM4EALDH1A1 | |
| Quinazoline SCHEMBL29356169 | 0.89 | EGFR (1.00) | EGFRPIK3CAPIK3CDKDM4EALDH1A1 | |
| Quinazoline SCHEMBL5920 | 0.89 | EGFR (1.00) | EGFRPIK3CAPIK3CDKDM4EALDH1A1 | |
| Quinazoline SCHEMBL29490398 | 0.89 | EGFR (1.00) | EGFRPIK3CAPIK3CDKDM4EALDH1A1 | |
| Quinazoline SCHEMBL561027 | 0.88 | EGFR (0.67) | EGFRPIK3CAPIK3CDKDM4EMAPKAPK2 | |
| Quinazoline SCHEMBL27275460 | 0.88 | EGFR (0.87) | EGFRPIK3CAPIK3CDALDH1A1CYP1A2 | |
| SCHEMBL3196932 | 0.87 | EGFR (0.95) | EGFRPIK3CAPIK3CDKDM4EALDH1A1 | |
| Quinazoline SCHEMBL3533306 | 0.87 | EGFR (0.95) | EGFRPIK3CAPIK3CDKDM4EALDH1A1 | |
| Quinazoline SCHEMBL4487630 | 0.87 | EGFR (0.95) | EGFRPIK3CAPIK3CDKDM4EALDH1A1 | |
| Quinazoline SCHEMBL21055790 | 0.87 | EGFR (0.95) | EGFRPIK3CAPIK3CDKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797087-A4 | CARBO- AND HETERO-CYCLIC ANTIBIOTICS AND USE THEREOF | ULYSSES PHARMACEUTICAL PRODUCT (CA) | 2009-06-03 | — | — | EP | disclosed |
| US-20080188499-A1 | Carbo- and Hetero-Cyclic Antibiotics and Use Thereof | ULYSSES PHARMACEUTICAL PRODUCTS INC. (CA) | 2008-08-07 | — | — | US | disclosed |
| CN-101027299-A | Carbon-and hetero-cyclic nitrofuran antibiotics and use thereof | ULYSSES PHARMACEUTICAL PRODUCT (CA) | 2007-08-29 | — | — | CN | disclosed |
| EP-1797087-A1 | CARBO- AND HETERO-CYCLIC ANTIBIOTICS AND USE THEREOF | Ulysses Pharmaceuticals Products Inc. (CA) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006032138-A1 | CARBO- AND HETERO-CYCLIC ANTIBIOTICS AND USE THEREOF | ULYSSES PHARMACEUTICAL PRODUCTS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188499-A1 | Carbo- and Hetero-Cyclic Antibiotics and Use Thereof | SLC7A1, CYP2C19, ABCB11 | EGFR 720/4885PIK3CA 1343/4885PIK3CD 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.